ANDA 207219, held by Yaopharma Co Ltd. Duloxetine Hydrochloride.
As of Nov 16, 2026, ANDA 207219 (Duloxetine Hydrochloride), held by Yaopharma Co Ltd, was first approved by FDA on Aug 16, 2019, with 0 approved supplements and 0 published complete response letters.
Duloxetine delayed-release capsules, USP are indicated for the treatment of:
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 16, 2019 | Original application | Approved | None posted |
| Duloxetine HydrochlorideEQ 20MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Discontinued |
| Duloxetine HydrochlorideEQ 30MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Discontinued |
| Duloxetine HydrochlorideEQ 60MG BASE · capsule, delayed rel pellets;oral | Duloxetine Hydrochloride | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters